Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Finished Goods (2018 - 2025)

TransMedics has reported Finished Goods over the past 8 years, most recently at $20.6 million for Q4 2025.

  • Quarterly results put Finished Goods at $20.6 million for Q4 2025, up 35.23% from a year ago — trailing twelve months through Dec 2025 was $20.6 million (up 35.23% YoY), and the annual figure for FY2025 was $20.6 million, up 35.23%.
  • Finished Goods for Q4 2025 was $20.6 million at TransMedics, down from $22.6 million in the prior quarter.
  • Over the last five years, Finished Goods for TMDX hit a ceiling of $22.6 million in Q3 2025 and a floor of $4.1 million in Q1 2021.
  • Median Finished Goods over the past 5 years was $13.6 million (2023), compared with a mean of $12.3 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 135.44% in 2023 and later decreased 20.85% in 2025.
  • TransMedics' Finished Goods stood at $5.7 million in 2021, then skyrocketed by 37.8% to $7.8 million in 2022, then skyrocketed by 87.5% to $14.6 million in 2023, then increased by 4.43% to $15.3 million in 2024, then skyrocketed by 35.23% to $20.6 million in 2025.
  • The last three reported values for Finished Goods were $20.6 million (Q4 2025), $22.6 million (Q3 2025), and $15.8 million (Q2 2025) per Business Quant data.